Industry Insights

  1. Confronting "Time Toxicity" In Global Oncology And Rare Disease Trials For Operational Excellence And Patient Retention 1/14/2026

    Time is the only truly finite resource in a clinical trial. Consultant Leila Cupersmith discusses how sponsors can better design trials with a lower time burden to boost enrollment, retention, and overall operational excellence.

  2. From Lab To Launch: Navigating The Transition To Commercial Readiness 1/13/2026

    Many clinical-stage companies start thinking about commercialization too late. FTI Consulting experts team up to provide guidance on getting started early.

  3. Navigating The Enrollment Bottleneck In Early Oncology Trials 1/12/2026

    Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

  4. Working (Well) With Patient Advocates: The Sponsor POV 1/12/2026

    Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

  5. Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit 1/12/2026

    Opus Genetics CEO George Magrath, MD, discusses how the company introduced virtual reality-enabled assessments and relied on digital endpoints to better measure participants’ vision changes.

  6. Working (Successfully) With Pharma: A PAG's Perspective 1/12/2026

    TSC Alliance President and CEO Kari Rosbeck details the patient advocacy group's unique and fruitful relationship with Aeovian Pharmaceuticals in developing the company's first-in-class selective mTORC1 inhibitor for TSC-related refractory epilepsy.

  7. Making Medical Innovation Matter To Patients With Simplified Trial Design 1/9/2026

    To be a leader in today’s environment, Lexicon Pharmaceuticals CMO Craig Granowitz, MD, Ph.D., says companies must embrace simplified clinical trial designs, which can reduce regulatory risks, lower R&D costs, and shorten clinical timelines.

  8. Build Or Buy: Adopting AI Agents In Life Sciences 1/8/2026

    Should your team build custom AI agents from scratch or partner with a ready-made solution? This practical guide cuts through the hype to reveal the strategic insights you need.

  9. Agentic AI Is Transforming Life Sciences Discovery And Operations 1/8/2026

    73% of pharma companies are planning or deploying agentic AI. Discover who’s leading and how intelligent agents are transforming R&D.

  10. FDA Pushes For Patient Voice: ePRO In Oncology Trials 1/8/2026

    FDA urges sponsors and CROs to include patient voices in oncology trials. Discover why it matters and how to start integrating this approach.